Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
Open Access
- 8 June 2020
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (5), 3919
- https://doi.org/10.15829/1560-4071-2020-3919
Abstract
Отношения и деятельность. Совет Экспертов прошел при поддержке компании АстраЗенека.This publication has 7 references indexed in Scilit:
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection FractionJournal of the American College of Cardiology, 2020
- Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th editionDiabetes mellitus, 2019
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionThe New England Journal of Medicine, 2019
- The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristicsEuropean Journal of Heart Failure, 2019
- Epidemiology of Heart FailurePublished by Springer Science and Business Media LLC ,2016
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes MellitusJournal of the American College of Cardiology, 2016
- Long-Term Trends in the Incidence of and Survival with Heart FailureThe New England Journal of Medicine, 2002